Skip to content

Study · Systematic review · 2019

2 results

Liraglutide for the Treatment of Obesity: Analyzing Published Reviews.

Pastor R, Tur JA

Current pharmaceutical design1 Jan 2019Cited by 4 (Europe PMC)

PMID31267857 (opens in a new tab)DOI10.2174/1381612825666190701155737 (opens in a new tab)PepBankPUB-31267857
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In adults treated for obesity, the included systematic reviews reported dose-dependent weight loss with liraglutide, with a plateau at the 3.0 mg dose that was reached just in men.

    In plain wordsIn three reviews of liraglutide for obesity, weight loss rose with dose; the plateau at 3.0 mg was reached just in men.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight loss by liraglutide dose
    Study

    n: not reported in source

    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In all studies, weight loss was registered in persons treated with liraglutide in a dose dependent form, reaching a plateau at 3.0 mg dose, which was reached just in men.
    1 context sentence
    Summary · context
    A total of 3 systematic reviews were finally included to be analyzed.
  2. 02HumanSystematic reviewSafety outcome

    In the three included systematic reviews of liraglutide for obesity, the most usual adverse events were gastrointestinal.

    In plain wordsIn three reviews of liraglutide for obesity, the most usual side effects were gastrointestinal.

    Peptide
    Liraglutide
    Outcome
    Not applicableMost usual adverse events
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Most usual adverse events were gastrointestinal.
    1 context sentence
    Summary · context
    A total of 3 systematic reviews were finally included to be analyzed.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:10 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.